Medco Rethinks Part D: Bailing Out or Mailing it In?

Medco shed over 100,000 Part D members in 2007 and the company couldn't be happier. Medco says it has no interest in serving the poorest Medicare beneficiaries, because they do not use mail order and can't be given viable economic incentives to do so. If other plans start to think like Medco, Part D advocates may have reasons to worry.

Medco Health Solutions Inc. just lost 25% of its biggest new market and the company couldn’t be happier about it. Actually, Medco could be a bit happier, if only they had lost more members.

Heading into 2007, Medco has approximately 320,000 Medicare beneficiaries enrolled in its stand-alone Part D drug insurance plan—a loss of...

More from Market Access

More from Pink Sheet

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s DMD Gene Therapy Elevidys

 

The European Medicines Agency has recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy, despite the product securing approvals in the US and other markets.